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Objective: The aim of this study was to investigate the clinical and laboratory features of patients with
the incidental diagnosis of endometrial adenocarcinoma (EC) during infertility work-up, with special
attention given to treatment approaches, recurrence rate, and fertility outcome.
Material and Methods: The medical records of 577 patients who were diagnosed with EC and treated
between 2007 and 2013 were included in the study. Out of 577 EC patients, 5.1% (n ¼ 30) were  40 years
of age. However, 10 patients had a history of infertility and had been diagnosed during evaluation for
infertility. Patients' clinical and laboratory data were reviewed retrospectively.
Results: The mean age at diagnosis was 34.3 ± 4.5 years and the mean duration of infertility was
5.1 ± 4.7 years. Immediate staging surgery was performed on three patients. The others were treated
with oral megestrol acetate and/or a levonorgestrel-containing intrauterine device (IUD) for 6 months.
The mean duration of postoperative or postdiagnostic follow-up was 44.7 ± 25.9 months. The disease
persistence and recurrence rates were 11.1% and 22.2%, respectively. Two patients achieved pregnancy
naturally or by assisted reproductive technology (ART) trial.
Conclusion: The investigation of patients during infertility work-up provides an opportunity to evaluate
the endometrium and its malignancies in young women, when the disease is in its early stage and
symptom free. The standard surgical treatment for early-stage EC is total hysterectomy with bilateral
salpingo-oophorectomy. However, conservative management of early stage EC with progestational drugs,
especially in young patients who wish to preserve their fertility, is acceptable with the possibility of
future pregnancies.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
The prevalence of endometrial adenocarcinoma (EC) in women
 40 years of age has been shown to be distinct in different studies
and is reported to be roughly between 2.9% and 14.4% [1e3]. The
incidence of EC in infertile women is not clear, even though it is
known that women undergoing infertility treatment have
increased risk of EC [4,5]. Genetic factors, nulliparity, insulin
resistance (with or without overt diabetes), and hypertension alsoen's Health Education and
cology, 06230, Hamamonu,
etinkaya).
bstetrics & Gynecology. Published bplay a role in EC genesis. However, young women diagnosed with
EC are often obese or overweight with anovulation [6]. Polycystic
ovarian syndrome (PCOS), thyroid hormone imbalance, increased
prolactin (PRL) levels, hyperandrogenism, hypercortisolism, etc.
may result in ovulatory diseases with progesterone insufﬁciency
and unopposed estrogenic stimulation, which increases the sus-
ceptibility of women to EC.
Abnormal uterine bleeding is the major complaint of women
with EC. Heavy menstruation or irregular spotting leads to early
perception of an abnormality by the women themselves. However,
in its early stages, EC might be indolent with no apparent symp-
toms. Most of the women undergo gynecological examination and
transvaginal ultrasonography in infertility clinics, perhaps for the
ﬁrst time, and routine investigations sometimes reveal endometrial
pathologies that need further evaluation.y Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
T. Gungor et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 309e313310EC is staged surgically according to the International Federation
of Gynecology and Obstetrics (FIGO) guidelines of 2009 [7]. The
staging operation is composed of total abdominal hysterectomy
with bilateral salpingo-oophorectomy, peritoneal washing, omen-
tectomy, and pelvic and paraaortic lymphadenectomy. A crucial
point is the age of thewomen at diagnosis, since the fertility issue is
extremely important. However, these patients usually have favor-
able prognosis with more frequent Grade I tumors and limited
myometrial invasion [8,9]. Thus administration of high-dose pro-
gesterone has been recommended in women with clinical Stage IA
and Grade I tumorswhowant to preserve their fertility [10]. In spite
of high-dose progesterone therapy, the recurrence rate of EC is 50%
[11,12]. As a result, the management of infertile women with EC
necessitates a frequent multidisciplinary approach with oncologic
surgeons and endocrinologists.
The investigation of endometrial pathologies of infertile women
is warranted since the incidence of infertility is approximately 15%
in high-income and 9e30% in low-income countries [13] and many
endometrial pathologies cause structural or functional inabilities
[14]. Subtle endometrial pathologies without any symptoms may
be noticed easily by blind endometrial sampling or by direct visu-
alization via hysteroscopy. However, the diagnosis of EC may be
overlooked if endometrial evaluation is postponed and an assisted
reproductive technology (ART) trial is performed in the case of
endometrial abnormality upon routine ultrasonographic investi-
gation. Thus, endometrial sampling before an ART trial is reason-
able in women with longstanding estrogenic stimulation and
endometrial irregularity despite the absence of symptoms [5].
In this study, we aimed to evaluate the clinical and laboratory
aspects of patients that incidentally were diagnosed with EC during
investigations for infertility and focused on the aforementioned
points in terms of etiology, treatment approaches, and course of the
disease.
Materials and methods
The present study was approved by the Institutional Review
Board of Zekai Tahir Burak Women’ Health Education and Research
Hospital, Ankara, Turkey where the study was conducted. The
medical records of 577 patients who had been diagnosed with EC
and treated in our tertiary reference center between 2007 and 2013
were reviewed retrospectively. Thirty out of the 577 EC patients
were  40 years of age. However, 10 patients with a history of
infertility had been diagnosed during evaluation for infertility.
From the hospital records of these 10 patients, data related to
age, past medical history, cycle property, symptoms, weight, body
mass index, cause of infertility, duration of infertility, and history of
previous ART trials were reviewed. Furthermore, the results of the
last Papanicolaou smear, endometrial thickness on transvaginal
ultrasonography, cycle Day 3 follicle stimulating hormone (FSH),
luteinizing hormone (LH), estradiol, PRL, thyroid stimulating hor-
mone, free triiodothyronine, and free thyroxine levels were
collected. The pathological reports of diagnostic endometrial
sampling with respect to histologic diagnosis and tumor grade
were checked. The cancer antigen-125 (CA-125), CA-199, CA-153,
carcinoembryonic antigen (CEA), and alpha-fetoprotein (AFP) levels
were evaluated after the diagnosis of EC. Data related to treatment,
disease stage, and ﬁndings in surgical specimens were browsed and
processes were evaluated.
The patients were staged surgically according to the FIGO 2009
guidelines with total abdominal hysterectomy, bilateral salpingo-
oophorectomy, peritoneal washing, omentectomy, and pelvic and
paraaortic lymphadenectomy or clinically due to their fertility
preferences. All of the patients on whom staging surgery was not
performed were treated with a 6 month oral course of megestrolacetate 160 mg/d 1  1 (Megace 160 mg pill, Haupt Pharma
Regensburg GMBH, Regensburg, Germany) with or without the
levonorgestrel-containing intrauterine device (IUD) (Mirena
levonorgestrel-releasing intrauterine system, Bayer Schering
Pharma Oy, Turku, Finland).
Statistical analysis
The descriptive statistical analysis was performed with SPSS for
Mac version 20 (SPSS for Mac Inc., Chicago, IL, USA). Values are
presented as mean ± standard deviation (SD) and range.
Results
In the study population, therewere 12 nulligravid patients (40%)
of whom eight (66%) were infertile and 14 nulliparous patients
(46%), while two (14%) had experienced recurrent pregnancy loss,
and 10 patients (33%) were infertile and diagnosed during infer-
tility workup. Table 1 presents the proﬁle of patients with EC and
infertility (Table 2).
Patients were diagnosed incidentally by endometrial sampling
because of abnormal visualization of the endometrial cavity during
transvaginal ultrasonography or ofﬁce hysteroscopy. However,
when they were asked after the diagnosis of EC about their periods
or previous symptoms, it was understood that three had pelvic pain
with oligomenorrhea, four had a recently noticed menometror-
rhagia, and two had pelvic pain with hypermenorrhea. There was
only one patient who had had no apparent symptoms.
The mean age at diagnosis was 34.3 ± 4.5 years (range,
28e40 years) and the mean duration of infertility was
5.1 ± 4.7 years (range, 1e18 years). Three patients had at least one
ART trial before the diagnosis and three had ART trials after the
medical therapy for EC. The mean weight at diagnosis was
77.7 ± 9.7 kg.
The last Papanicolaou smear (Pap test) was reported to be
normal in ﬁve patients and the other ﬁve patients had inﬂamma-
tory reactive alterations. The mean value of the endometrial
thickness was 22.41 ± 18.9 mm on transvaginal ultrasonography.
Based on the Rotterdam 2003 criteria [15], PCOS was diagnosed in
seven patients (70%).
The mean values ± SD of cycle Day 3 FSH, LH, estradiol, PRL,
thyroid stimulating hormone, free triiodothyronine, and free
thyroxine levels were: 5.5 ± 1.2 mIU/mL, 9.5 ± 5.3 mIU/mL,
62.09 ± 18.5 pg/mL, 23.1 ± 20.9 ng/mL, 1.8 ± 0.7 uIU/mL, 3.5 ± 0.4
pg/mL, and 1.3 ± 0.3 ng/dL, respectively.
The endometrial sampling results revealed Grade I EC in four,
Grade II EC in one, complex atypical hyperplasia (CAH) with Grade I
EC in two, CAH with Grade I EC could not be excluded in two, and
complex hyperplasia without atypia with Grade I EC could not be
excluded in one patient.
The mean values ± SD of the CA-125, CA-199, CA-153, CEA, and
AFP levels after the diagnosis of EC were: 31.9 ± 24.2 U/mL,
29.7 ± 71.2 U/mL, 19.6 ± 9.8 U/mL, 0.9 ± 0.7 ng/mL, and 1.9 ± 1.1 ng/
mL, respectively. Elevations of the CA-125 and CA-199 tumor
markers above the current cut-off value were diagnosed in ﬁve and
two patients, respectively.
The mean duration of postoperative or postdiagnostic follow-up
was 44.7 ± 25.9 months (range, 3e75 months). Only one patient
who was under medical treatment dropped out of the regular
postoperative check visits 3 months after the diagnosis.
Three of the patients (P1, P2, P3) elected to have immediate
surgical staging instead of progesterone therapy. In the permanent
pathology evaluation: P1 had architectural Grade I, nuclear Grade II,
Stage IB, EC with deep myometrial invasion and lymphovascular
space involvement (LVSI), and had postoperative adjuvant
Table 1
Proﬁle of patients with endometrial adenocarcinoma (EC) diagnosed on infertility investigations.
Patient Age
(y)
Duration of
infertility (y)
Infertility
cause
BMI
(kg/m2)
Previous
pregnancy
ART
history
PCOS Medical illness Diagnosis
1 28 1 OD 24 G0P0 e þ e P&C
2 31 3 Recurrent
abortion
22 G3P0A3 þ (PD) e Multiple myomectomy operations H/S
3 38 3 OD 41 G0P0 e þ HT, Cushing's syndrome, multiple myoma P&C
4 40 5 Recurrent
abortion
21 G2P0A2 e e Impaired fasting glucose, decreased
protein S and protein C
activity, PRL > 20 ng/mL
H/S
5 39 6 OD 28 G0P0 þ (PD&AD) þ Metabolic syndrome, multiple myoma H/S
6 34 18 OD 20 G0P0 þ (PD&AD) þ Multiple myoma, PRL > 20 ng/mL H/S
7 33 5 OD 24 G0P0 e þ e H/S
8 30 3 OD 32 G0P0 þ (AD) þ e H/S
9 30 2 Unexplained 26 G0P0 e e Hypothyroidism H/S
10 40 5 OD 26 G0P0 Unknown þ Hypothyroidism P&C
A ¼ abortus; AD ¼ after the diagnosis; BMI ¼ body mass index; G ¼ gravida; H/S ¼ hysteroscopy; HT ¼ hypertension; OD ¼ ovulatory disorder; P ¼ parity; P&C ¼ probe
curettage; PCOS ¼ polycystic ovarian syndrome; PD ¼ previous the diagnosis; PRL ¼ prolactin.
Table 2
Treatment and clinical course of 10 patients with endometrial adenocarcinoma (EC) detected on infertility investigations.
Patient Endometrial sampling Initial treatment Follow-up
(mo)
Treatment outcome ART Pregnancy
after diagnosis
Clinical course Final diagnosis
1 CAH þ AG-I EC could
not be excluded
Surgery 70 CR e e CR AG-I, NG-II, stage IB EC
with deep myometrial
invasion and (þ) LVSI
AT: Radiotherapy
2 CAH þ AG-I EC could
not be excluded
Surgery 25 CR e e CR AG-I, NG-II, stage IA
EC with (þ) LVSI
AT: None
3 CAH þ AG-I EC Surgery 42 CR e e CR Simple atypical
hyperplasia without
EC
4 NG-II EC 6 Mo MA 19 Persistence at 6th mos.
Scheduled for surgery
e e CR AG-I, NG-II, stage IB
EC with (þ) LVSI
AT: Radiotherapy
5 CH without atypia &
NG-I EC could not
be excluded
6 Mo MA 63 Recurrence in the form
of CAH at 18th mo after
failed
ART trial.
Scheduled for surgery
þ e CR AG-I, NG-I, stage
IA EC without LVSI
AT: None
6 NG-I EC 6 Mo MA
and LNG-IUD
24 Abortion after ART trial
at 12th mo. Scheduled
for surgery
þ G1P0A1 CR AG-I, NG-I, stage
IA EC without LVSI
AT: None
7 NG-I EC 6 Mo MA
and LNG-IUD
75 CR e G2P2
(Spontaneous)
CR Clinical Stage IA
8 CAH þ NG-I EC 6 Mo MA
and LNG-IUD
51 CR þ G2P1 Recurrence in
the form of
CAH at 36th
mo.
Second course
of medical
therapy. CR
Clinical Stage IA
9 NG-I EC 6 Mo MA
and LNG-IUD
75 CR Not yet e CR Clinical Stage IA
10 NG-I EC 6 Mo MA
and LNG-IUD
3 Unknown Unknown Unknown Unknown Clinical Stage IA
Dropped out
A ¼ abortion; AG ¼ architectural grade; ART ¼ assisted reproductive technology after EC diagnosis; AT ¼ adjuvant therapy; CAH ¼ complex atypical hyperplasia;
CR ¼ complete response; G ¼ gravida; LNG-IUD ¼ levonorgestrel-containing intrauterine device; LVSI ¼ lymphovascular space involvement; MA ¼ megestrol acetate;
NG ¼ nuclear grade; P ¼ parity.
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IA, ECwith LVSI, and had no postoperative adjuvant therapy; and P3
was diagnosed with simple atypical hyperplasia without EC. Her
previous tissue biopsy had revealed CAH with Grade I EC.
Three other patients (P4, P5, P6) with suspected malignancies
were administered 6 months of oral progesterone therapy. Only
one of them used the levonorgestrel-containing IUD in addition to
oral progesterone. At the 6th month, P4 had disease persistenceconﬁrmed by tissue biopsy and underwent surgery. She had
architectural Grade I, nuclear Grade II, Stage IB, EC with LVSI, and
underwent adjuvant radiotherapy. P5 had ART trial that resulted in
failure and at the 18th month underwent surgery due to disease
recurrence in the form of CAH in the endometrial biopsy. P6 had
elected surgery at the 12th month after aborting her ART pregnancy.
P5 and P6 had architectural and nuclear Grade I, Stage IA, EC
without LVSI, and they had no adjuvant therapy.
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endometrial cavity was affected by the tumor in two patients (Stage
IA and Stage IB). The isthmus was invaded by the tumor in three
patients (2 Stage IB and 1 Stage IA) without cervical involvement.
There was no adnexal involvement. Two patients, one with bilateral,
had follicular cysts > 3 cm. Peritoneal washings were negative for
malignant cells. Omentectomy evaluations revealed chronic
inﬂammation in one and mature adipose tissue in ﬁve patients.
Appendectomies were performed in all of the patients, which
revealed obliteration in one and periappendicitis in another patient.
The LVSI was seen in only three patients with Stage IA and Stage IB
disease. The mean collected pelvic and paraaortic lymph node count
was 71.8 ± 26 (range, 37e111). Three patients had multiple myoma
uteri in the uterine specimens and another one had a history of three
myomectomy operations. One of the operated patients had meta-
bolic syndrome, one had Cushing's syndrome with morbid obesity
and hypertension, and one had impaired fasting glucose levels with
decreased protein S and protein c activity.
The other four patients (40%) were treated with oral meges-
trol acetate and levonorgestrel-containing IUD for 6 months.
Endometrial biopsy evaluations were performed thereafter at
3 month intervals. However, one of them dropped out of the
follow-up in the 3rd month. Two patients were under levothyr-
oxine supplementation due to Hashimato's disease. After treat-
ment, one of the patients had two spontaneous pregnancies and
deliveries. Another patient had two ART trials and had one de-
livery, and developed CAH in the 36th month. She was treated
with a second course of medical therapy with the same protocol
and is now disease free. The last patient has had no ART trial yet.
The mean duration of postoperative follow-up was
51 ± 33.9 months in these four patients and three of them are
still on close follow-up.
Disease persistence or recurrence was seen after oral therapy in
the patients with Stage IB (P4) and Stage IA (P5). Another patient
with Stage IA (P8) disease and treated with both oral and
levonorgestrel-containing IUD had recurrent disease in the form of
CAH. Thus, the rates of disease persistence and recurrence were
reported to be 11.1% and 22.2% in the infertile patients with EC.
Furthermore, the disease persistence and recurrence rates of the
whole study population (n ¼ 577) were reported to be 14.2% and
28.5%, respectively.
Discussion
Nowadays, the number of young womenwith EC is increasing in
developing countries due to alterations of diet and lifestyle, such as
increasing obesity and getting married in later reproductive years.
The literature data presenting the increased incidence of EC in
women  40 years of age leads to treatment challenges, especially
inwomenwhowish to preserve their fertility [1,2]. Fortunately, the
prognosis of EC in this group of patients is known to be promising
assuming the tumor is well differentiated and without myometrial
invasion, with a 5-year survival rate of 93% [16].
The incidence of infertility is estimated to be between 8.5% and
20% in industrialized countries [17] and it is much more common
than the 5% incidence of EC inwomen  40 years of age. Uterotubal
peritoneal factors, ovulatory disorders, and unexplained infertility
create the main components of the female infertility. Nevertheless,
endometrial pathologies, such as CAH or EC may predispose pa-
tients to infertility [18] or vice versa [19]. Therefore, investigations
during infertility work-up provide an opportunity to evaluate the
endometrium and its pathologies in young women, when the dis-
ease is in its early stage and still symptom free.
Based on our data, the incidence of EC was 5.1% in women 
40 years of age. Infertility, with the most frequently encounteredovulatory disorder, was a risk factor in 33% of EC patients (n¼ 10) at
 40 years of age with the estimated incidence of 1.7%. Almost 70%
of the patients with a history of infertility had Stage IA disease.
Based on previous reports in the literature, it is known that EC is
most commonly encountered in overweight or obese women [20].
However, it is also clear that familial cancer syndromes (Lynch
syndrome), nulliparity, history of infertility, insulin resistance, and
PCOS with its altered hormonal milieu may contribute to the
development of EC in normal weight women [21]. The mean body
mass index in infertile women with EC was 26.4 ± 6.2 kg/m2 in our
study with the ratio of normal weight women at 50%. There was
only one patient with morbid obesity. According to the preopera-
tive diagnostic evaluations, increased endometrial thickness was
the most remarkable sign for endometrial pathology necessitating
probe curettage in three patients and hysteroscopy in seven pa-
tients. None of the patients had abnormal glandular cells in the Pap
test. Day 3 hormone levels presented increased estrogen levels over
40 pg/mL in all patients with LH/FSH ratio > 2 in 60%. The
accompanying conditions with EC were PCOS, hypothyroidism,
hypercortisolism, hypertension, impaired fasting glucose levels,
hyperprolactinemia, and history of previous ART trials. The pres-
ence of multiple myoma was also evidence that supported the es-
trogenic effect in three patients [22].
Serum CA-125 levels have been used clinically for EC and
increased levels correlate with the disease stage or several his-
topathologic factors [23]. This appears to predict lymph node
metastasis and advanced stage disease preoperatively [23,24].
Although the optimal CA-125 cut-off value for premenopausal
patients with endometrial cancer was reported to be 105 U/m: in
the literature [23], there were no patients with CA-125 values
above this threshold level in our study. However, elevation of the
CA-125 tumor marker above the current cut-off value of 35 U/mL
was diagnosed in ﬁve patients (n ¼ 3, Stage IA and n ¼ 2, Stage IB
EC) and elevated values were seen in patients with Stage IB
disease, deep myometrial invasion, (þ) LVSI and isthmic
involvement. There was no patient with positive lymph node
metastasis in our study and based on this data, we could not
demonstrate any correlation with lymphatic involvement and
preoperative CA-125 levels. Moreover, the concurrent CA-199
tumor marker was diagnosed above the current cut-off value of
37 U/mL in only two patients (n ¼ 1, Stage IA and n ¼ 1, Stage IB
EC). The levels of CA-153, CEA, or AFP levels were within the
normal range in all infertile patients with EC. The level of pro-
lactin hormone, which was previously reported to have a positive
correlation with the tumor stage and grade in EC [25], increased
in only two patients.
As previously mentioned in the literature, conservative man-
agement of EC with oral progestational drugs in young patients
with early stage disease is effective without compromising onco-
logical outcome, withmean persistence and recurrence rates of 21%
and 33%, respectively [26]. Furthermore, Wang et al [27] reported
that the crude recurrence rate was 50%, and the 5-, 10-, and 15-year
cumulative recurrence-free survival rates were 51.0%, 51.0%, and
34.0%, respectively, in their series, which was composed of young
aged women with EC. They also drew attention to the substantial
risk of late recurrences [27]. The disease persistence and recurrence
rates of the whole study population (n ¼ 577) were 14.2% and
28.5%, respectively, in our study. We operated on three patients
immediately and treated the remaining seven patients medically
according to the patients' desire in the infertile population (n ¼ 10)
with EC. The oral progestational drug was megestrol acetate in all
patients with the same dose regimen. Only ﬁve patients also used
the levonorgestrel-containing IUD. The rates of disease persistence
and recurrence were reported to be 11.1% (1/9) and 22.2% (2/9) in
the infertile patients with EC; however, the case number was small.
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pathologies diagnosed in the hysterectomy specimens are known
to show a 16% discrepancy [28]. There was only one patient with a
diagnosis of no malignancy in the hysterectomy specimen. How-
ever, the preoperative tissue diagnosis was CAH with Grade I EC. As
suggested in the literature, this patient was accepted as having focal
Grade I EC possibly on a polyp structure and postoperative regular
check visits were recommended to this patient.
The present study has some limitations. The retrospective na-
ture of this study is one of the obstacles. Furthermore, it cannot
present the EC incidence in the infertile women because this study
was not conducted in a fertility clinic. We studied a group of
women  40 years of age with the diagnosis of EC in our gyneco-
logic oncology clinic and evaluated their clinical data. A history of
diagnosis during the infertility work-up was seen in 10 of the 577
EC patients with an incidence of 1.7%. We roughly know the history
of the ART trials prior to or after the diagnosis. What speciﬁc drugs
and which treatment protocols had been used were not always
clear. Another limitation was that we did not evaluate our patients
with the genetic testing for Lynch syndrome, despite 50% of the
women with EC being normal weight; nor were we aware of their
hormone receptor status.
In conclusion, conservative management of EC, especially in
young patients with fertility desire, is acceptable only after the
patients are fully informed about the risks and beneﬁts. Two pa-
tients in this study achieved pregnancy both spontaneously and
with an ART trial. To the best of our knowledge, this study includes
all the clear data related to patients' proﬁles and clinical properties
with a sufﬁciently long duration of follow-up. Further prospective
studies with larger numbers are needed to clearly delineate the EC
incidence in infertile women and the efﬁcacy of medical treatment
instead of staging surgery in the early stages of the disease.
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